Theranos Whistleblower Tyler Shultz Warns AI Boom Is Ripe for Fraud
Theranos whistleblower Tyler Shultz warns opaque AI startups make due diligence harder, while Elizabeth Holmes prepares a comeback through Haemanthus.
Summary
As of October 30, 2026, Nathan Fielder and Lance Oppenheim’s “You Can See Everything” is driving national debate as one of the highest-grossing documentaries ever. Following Elizabeth Holmes, a mother of two, before her more than 11-year federal prison sentence, it avoids portraying her as either victim or master manipulator and emphasizes her ability to attract pity. After a decade of attention, the film also minimizes Theranos’ faulty patient results and targeted harassment of Tyler Shultz, whose first post-college job there led him to expose blood-testing machines that reached Walgreens. Theranos used its devices for only a fraction of tests, outsourced the rest and reached about a $10 billion valuation without working technology.
Shultz warns that unprofitable AI companies raising capital at trillion-dollar valuations offer similarly fertile conditions for deception because investors may struggle to distinguish genuine innovation from a ChatGPT wrapper. Holmes withheld scientific evidence as trade secrets, deterring leading Silicon Valley venture firms, but raised heavily from individuals including the DeVos and Walton families. Shultz’s grandfather, former U.S. Secretary of State and Treasury Secretary George Shultz, invested and joined the board. Tyler Shultz says Holmes scaled a 30-minute, $100,000 angel-investment model to $100 million, potentially creating the largest angel round ever. Holmes is now preparing a second act with partner and hotel heir Billy Evans through Haemanthus, described as “Theranos 2.0” and reportedly funded with about $20 million, leaving Shultz uncertain about what follows.
Positives
- Tyler Shultz’s disclosures exposed Theranos devices that delivered dangerously inaccurate results after reaching Walgreens patients.
- Leading Silicon Valley venture firms resisted Theranos after it withheld scientific evidence under trade-secret claims.
- “You Can See Everything” has renewed national scrutiny of Elizabeth Holmes and Theranos’ conduct.
- The Theranos collapse established due diligence as a critical safeguard for technology investors.
Risks & concerns
- Theranos reached about a $10 billion valuation despite using its own nonworking machines for only a fraction of tests.
- DeVos and Walton family investments showed how individual backers could provide vast funding without scientific validation.
- AI investors may struggle to separate original technology from ChatGPT wrappers as unprofitable companies pursue trillion-dollar valuations.
- Haemanthus, called “Theranos 2.0,” has reportedly raised about $20 million while Holmes serves a federal prison sentence.
- The documentary minimizes Theranos’ faulty medical results and its targeted harassment of whistleblower Tyler Shultz.